|
gptkbp:instanceOf
|
gptkb:chemical_compound
antiviral drug
antineoplastic agent
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01BC07
|
|
gptkbp:bioavailability
|
subcutaneous 89%
|
|
gptkbp:brand
|
gptkb:Vidaza
|
|
gptkbp:CASNumber
|
320-67-2
|
|
gptkbp:contraindication
|
hypersensitivity to azacitidine
|
|
gptkbp:developedBy
|
gptkb:Pharmion
|
|
gptkbp:eliminationHalfLife
|
4 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasInChIKey
|
XOLMWWXRAYXKRY-GQCTYLIASA-N
|
|
gptkbp:hasMolecularFormula
|
C8H12N4O5
|
|
gptkbp:hasSMILES
|
C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
azacitidine
|
|
gptkbp:KEGGID
|
D00294
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA methyltransferase inhibitor
|
|
gptkbp:MeSH_ID
|
gptkb:D000077207
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
244.21 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:PubChem_CID
|
gptkb:DB00928
9444
CHEMBL1387
9071
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
injection site reaction
neutropenia
thrombocytopenia
|
|
gptkbp:synonym
|
gptkb:5-azacytidine
|
|
gptkbp:UNII
|
M801H13NRU
|
|
gptkbp:usedFor
|
gptkb:acute_myeloid_leukemia
myelodysplastic syndromes
|
|
gptkbp:bfsParent
|
gptkb:Vidaza
gptkb:Venclexta
|
|
gptkbp:bfsLayer
|
7
|